Hepatocellular carcinoma (HCC) is an aggressive tumor of the liver with annual incidence of 1-6% in at risk patients with liver cirrhosis [1, 2]). Most patients have symptoms only in advanced stage HCC, impeding early detection of the tumor. The 5-year survival rate is <10% if HCC is diagnosed after symptoms occur in advanced stage .However, 5-year survival rates of 50 – 70% are possible when the tumor is diagnosed at an early stage . Therefore, current guidelines recommend to enroll patients with liver cirrhosis in HCC surveillance programs using semiannual abdominal sonography [4,5]. Unfortunately, the sensitivity of sonography for detecting early stage HCC in liver cirrhosis is less than 50% according to a recent meta-analysis . Addition of the widely used serum biomarker AFP (alpha-feto protein) to sonography only marginally improved sensitivity for early HCC and is not recommended in HCC surveillance due to its low sensitivity and specificity. Thus, there is a strong clinical need for a non-invasive test to supplement abdominal sonography in HCC surveillance to improve detection of early stage HCC.
HERMES follows a two-step approach with development and initial testing of the metabolite constellation in retrospective case-control cohorts and a subsequent validation including transfer to the target population in a prospective multicenter study**.
Serum samples of cirrhotic patients with and without HCC
High-resolution imaging with liver biopsy if necessary
Metabolomics studies allow the analysis of the entire metabolite spectrum (metabolome) of a biospecimen to detect rising and falling concentrations of endogenous substances and to associate them with pathological processes. numares uses its precise, fast and flexible analytical AXINON® System, which allows simultaneous detection of metabolites in a highly reproducible single analytical step without predefined selection criteria. Using this untargeted metabolic analysis, numares has identified a metabolite constellation in serum for detection of early HCC using a retrospective case-control data set. In an independent sample set not used for biomarker discovery, the metabolite constellation was able to detect early HCC in high-risk patients with liver cirrhosis. Moreover, preliminary work suggests that this metabolite constellation, in combination with abdominal sonography, can provide significant added value over sonography alone. In a first step, the metabolite constellation will be tested in additional retrospective case/control cohorts. In a second step, these results will be validated further and transferred to the actual surveillance setting in a prospective multicentre study**.
**The prospective multicentre study is sponsored by the German Federal Ministry of Education and Research, field of action “Gesundheitswirtschaft im Rahmenprogramm Gesundheitsforschung”, contract number 13GW0307.
numares successfully identified a metabolite constellation in serum for detection of early stage HCC*.
1. Forner, A., M. Reig, and J. Bruix, Hepatocellular carcinoma. Lancet, 2018. 391(10127): p. 1301-1314.
2. Ioannou, G.N., et al., Incidence and predictors of hepatocellular carcinoma in patients with cirrhosis. Clin Gastroenterol Hepatol, 2007. 5(8): p. 938-45, 945 e1-4.
3. Llovet, J.M., A. Burroughs, and J. Bruix, Hepatocellular carcinoma. Lancet, 2003. 362(9399): p. 1907-17.
4. European Association for the Study of the Liver. Electronic address, e.e.e. and L. European Association for the Study of the, EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. J Hepatol, 2018.
5. Heimbach, J.K., et al., AASLD guidelines for the treatment of hepatocellular carcinoma. Hepatology, 2018. 67(1): p. 358-380.
6. Tzartzeva, K., et al., Surveillance Imaging and Alpha Fetoprotein for Early Detection of Hepatocellular Carcinoma in Patients With Cirrhosis: A Meta-analysis. Gastroenterology, 2018. 154(6): p. 1706-1718 e1.
*numares’ products are not yet available for sale within the United States; they have not yet been approved or cleared by the U.S. Food and Drug Administration.
Development and validation of an NMR based metabolite constellation determining glomerular filtration rate for a more accurate picture of the underlying kidney function.
“The numares‘ metabolomics approach bears the innovative und non-invasive potential to determine severity and complexity of CKD without using eGFR equations based on creatinine and cystatin C. Furthermore, the metabolite panel offers chances for studying CKD induced co-morbidities.“,
Professor Emeritus Jochen Ehrich, MD, DCMT (London), Honorary Member of the European Society for Paediatric Nephrology
According to the KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease, the severity of CKD should be classified based on glomerular filtration rate (GFR), etiology and albuminuria. The gold standards to determine measured GFR are inulin and other exogenous substances [1, 2, 3]. These mGFR methods are expensive, invasive, time-consuming and very limited for routine use in out-patient settings. Therefore, GFR is mostly estimated by...
Quantitative evaluation of the diagnostic accuracy (AUC value, sensitivity, and specificity) of AXINON® renalTX-SCORE-U100® for the detection of acute renal allograft rejections
“A non-invasive diagnostic test for close-monitoring of kidney transplant patients and minimizing the number of potential graft-harming biopsies for earliest therapy intervention to preserve the kidney“,
Eva-Maria Huber, Study Manager Clinical Development, numares AG
Kidney transplantation is the treatment method of choice for patients with terminal kidney failure . Transplant patients require frequent follow-up examinations to detect potential complications at an early stage. Therefore, biopsies are performed during aftercare. They are generally considered to be safe, but it remains an invasive procedure with a risk...
Development and Evaluation of a metabolite constellation for the diagnosis of bladder cancer in patients with persistent microhaematuria.
“A minimal invasive diagnostic test for a reliable detection of bladder cancer.“
Amauri G.S. Santamaría, Study Manager Clinical Development, numares AG
Urinary bladder cancer (BCa) is a malignant tumour that usually develops in the mucous membrane (urothelial carcinoma) of the bladder. The symptoms are relatively unspecific. One of the earliest cardinal symptoms of BCa is microscopically detectable haematuria, so-called microhaematuria, . However, microhaematuria commonly has benign causes, such as infection, benign prostate enlargement or...
Development and Validation of an NMR-based metabolite constellation that early indicates the transition of relapsing-remitting (RRMS) to secondary progressive multiple sclerosis (SPMS).
“A serum-based test for early diagnosis of the RRMS-to-SPMS transition to allow timely therapy adjustment”
Dr. Eric Schiffer, Head of Clinical Development, numares AG
Multiple sclerosis (MS) is considered to be an immune-mediated disease in which the body’s own defence cells attack the central nervous system. MS involves inflammatory and neurodegenerative processes that damage the insulating myelin sheaths of nerve fibers and the nerve cells themselves. While about 10-15% of patients begin the disease with primary progressive MS (PPMS) showing continuously worsening of symptoms from disease onset, the majority of patients are initially diagnosed...